14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” Gefitinib can cause hair loss without scarring.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
August 2024 in “Postgraduate Medical Journal” A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
1 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
184 citations
,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
4 citations
,
November 2020 in “Acta Dermato Venereologica” Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.
October 2014 in “Cancer research” Blocking mTORC1 reduces skin tumor growth in mice.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
4 citations
,
June 2025 in “MedComm” PROTACs show promise for cancer treatment, but designing them effectively is challenging.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
26 citations
,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
21 citations
,
June 2017 in “Case Reports in Dermatology” Reducing gefitinib dosage improved hair loss, but scarring remained.
September 2014 in “SciBX” JAK inhibitors may help treat alopecia areata and promote hair regrowth.
12 citations
,
May 2015 in “Journal of the National Comprehensive Cancer Network” Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.